GlassScriptPhysician profile
Gregory A Buford
NPI 1558302380
$300,969.83
in general payments reported to CMS, 2019-2025
17 companies · $75K in 2025
The $75K reported for 2025 was more than what 99% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
See the full distribution for Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $93K · 2020: $21K · 2021: $9,478 · 2022: $55K · 2023: $42K · 2024: $4,872 · 2025: $75K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $85K · Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,974 · Food and Beverage: $5,115 · Travel and Lodging: $2,318 · Education: $59.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $85,000.00 |
| Consulting Fee | $22,766.67 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,973.60 |
| Food and Beverage | $5,114.59 |
| Travel and Lodging | $2,317.80 |
| Education | $59.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $170,185.53 | 2019-2023 | |
| Abbvie INC. | $115,461.72 | 2022-2025 | Botox, Natrelle Saline-Filled Breast Implants |
| Galderma Laboratories, L.P. | $6,607.69 | 2021-2025 | Dysport |
| Apyx Medical Corporation | $5,246.01 | 2019-2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $2,350.17 | 2022-2023 | |
| Mentor Worldwide LLC | $221.21 | 2021 | |
| Innovation Technologies INC | $178.80 | 2025 | Irrisept |
| Merz North America, INC. | $171.22 | 2022-2023 | Xeomin |
| Tepha INC | $171.09 | 2019 | |
| Motiva USA, LLC | $140.03 | 2025 | |
| Acelrx Pharmaceuticals, INC. | $58.42 | 2020 | |
| Revance Therapeutics, INC. | $39.53 | 2025 | Daxxify |
| Endo Pharmaceuticals INC. | $36.32 | 2019 | |
| Medtronic, INC. | $35.00 | 2022 | |
| Tela Bio, INC. | $34.67 | 2022-2024 | Ovitex 2s |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $32.42 | 2025 | Exparel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Buford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.